Kailera IPO shines as GLP-1 doubts spark interest in GIP-glucagon obesity strategy
Kailera Therapeutics raised $625 million in an IPO—the largest ever for a drug company—while researchers question the necessity of GLP-1 for obesity therapy and consider GIP-glucagon as a potentially better, more tolerable dual target; the Readout also notes FDA interest in expanding testosterone therapy for libido.